In the third quarter, Pacific Biosciences reported $38.44 million in revenue, falling 3.8% year-over-year and missing analysts’ projections by 4.5%. This marks the fifth revenue forecast miss for the company over the past two years, reflecting persistent challenges in top-line growth.

Analysts anticipate fourth-quarter revenue of $43.04 million, representing a 9.7% year-over-year increase from the 32.8% decline recorded in the same period last year. The consensus forecasts an adjusted loss of $0.13 per share, with estimates remaining stable over the past month.

Within the life sciences tools and services sector, Illumina posted 5% revenue growth and beat estimates by 3.2% but saw its share price drop 10.4%, while Medpace delivered 32% revenue growth and topped forecasts by 3.3% but declined 16.1%. These mixed peer results signal potential market volatility for PacBio post-earnings.

Shares of Pacific Biosciences have fallen 9.9% over the past month, underperforming the sector average decline of 3.7%. The stock trades around $1.82, below an average analyst target of $2.42, highlighting cautious sentiment ahead of the earnings announcement.